News | June 04, 2012

Jury Awards $6.4 Million for Heart Attack Misdiagnosis

ER doctors misdiagnosed heart condition, released man with Motrin and antibiotic

June 4, 2012 — A jury awarded $6.4 million to the young children of a Philadelphia man after finding that emergency room doctors misdiagnosed a heart condition as pneumonia and discharged him from the hospital, only for him to die months later.

After seven days of testimony, the jury found that Robert M. McNamara, M.D., Marsha W. Edwards, M.D. and Temple University Hospital were negligent in the care of Derrick Harlem, 38. The verdict is believed to be among the largest Pennsylvania medical malpractice awards involving a death in years. Jurors reached the verdict three years to the day after Harlem's misdiagnosed heart condition.

"This is a fair and just verdict," said Matthew Casey, a founding partner at Ross Feller Casey, LLP, who litigated the case on behalf of Harlem's children. "These young children lost their dad and no amount of money can replace him. They would gladly give the money back for more time with their dad."

On May 31, 2009, Harlem passed out while playing basketball and was transported to the Temple University Hospital’s emergency department. Despite symptoms consistent with a heart attack, Harlem was diagnosed with pneumonia and released later that day after being given Motrin and Azithromycin.

Three months later, Harlem again passed out while playing basketball and was again taken to Temple's emergency department. This time, he had suffered a massive heart attack as a result of what had become a complete arterial blockage. Harlem remained in a pharmacologically induced coma until his death Nov. 12, 2009. He left behind five children, now ages 3-11.

The verdict includes $5.5 million for the loss of guidance, tutelage and moral upbringing.

For more information: www.rossfellercasey.com/practice-areas/medical-malpractice/


Related Content

News | Cath Lab

May 13, 2026 — According to a recently released report, the global cath lab services market was valued at $46.0 billion ...

Home May 13, 2026
Home
News | Cath Lab

April 16, 2026 — A national study led by investigators from Cedars-Sinai Health Sciences University found that ...

Home April 20, 2026
Home
News | Cath Lab

April 6, 2026 —Stereotaxis has received U.S. Food and Drug Administration 510(k) clearance for its Synchrony system ...

Home April 07, 2026
Home
News | Cath Lab

March 31, 2026 — Solo Pace Inc. has announced the commercial release of the SoloPace Fusion Temporary Pacing System. The ...

Home April 03, 2026
Home
News | Cath Lab

March 25, 2026 — Royal Philips has launched its intuitive interventional guidance platform, IntraSight Plus, which is ...

Home March 26, 2026
Home
Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
Subscribe Now